A detailed history of Congress Wealth Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Congress Wealth Management LLC holds 35,248 shares of VRTX stock, worth $14.4 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
35,248
Previous 31,779 10.92%
Holding current value
$14.4 Million
Previous $14.9 Million 10.06%
% of portfolio
0.23%
Previous 0.24%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $1.6 Million - $1.75 Million
3,469 Added 10.92%
35,248 $16.4 Million
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $11.5 Million - $14.3 Million
29,371 Added 1219.73%
31,779 $14.9 Million
Q1 2024

Apr 18, 2024

BUY
$407.69 - $446.08 $541,412 - $592,394
1,328 Added 122.96%
2,408 $1.01 Million
Q4 2023

Feb 09, 2024

BUY
$343.0 - $410.68 $96,040 - $114,990
280 Added 35.0%
1,080 $439,000
Q3 2023

Oct 30, 2023

BUY
$338.18 - $362.46 $19,276 - $20,660
57 Added 7.67%
800 $278,000
Q2 2023

Jul 13, 2023

BUY
$314.42 - $351.91 $25,153 - $28,152
80 Added 12.07%
743 $261,000
Q1 2023

Apr 14, 2023

SELL
$283.23 - $323.1 $46,166 - $52,665
-163 Reduced 19.73%
663 $208,000
Q4 2022

Feb 02, 2023

BUY
$285.76 - $321.48 $32,862 - $36,970
115 Added 16.17%
826 $238,000
Q3 2022

Nov 08, 2022

BUY
$273.83 - $305.53 $194,693 - $217,231
711 New
711 $206,000
Q2 2022

Aug 11, 2022

SELL
$234.96 - $292.55 $240,834 - $299,863
-1,025 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $664 - $782
3 Added 0.29%
1,025 $267,000
Q4 2021

Feb 04, 2022

BUY
$177.01 - $223.45 $180,904 - $228,365
1,022 New
1,022 $224,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Congress Wealth Management LLC Portfolio

Follow Congress Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Congress Wealth Management LLC , based on Form 13F filings with the SEC.

News

Stay updated on Congress Wealth Management LLC with notifications on news.